Greatbatch, Inc. today announced that the company will establish an
Active Implantable Medical Device (AIMD) Research and Development Center in
Singapore.
Greatbatch, Inc. today announced
that the company will establish an Active Implantable Medical Device (AIMD)
Research and Development Center in Singapore – the first of its kind in the
country.
The establishment of this center
is a continuation of Greatbatch’s medical device strategy and the first step of
its Asia Pacific strategy to engage in emerging healthcare markets.
“Many factors contributed to our
decision to establish the first multinational R&D center for active
implantable medical devices in Singapore, including the nation’s commitment to
developing its biomedical sciences cluster, as evidenced by its strong
investment in research organizations,” said Thomas J. Hook, President and CEO
of Greatbatch.
The Greatbatch Singapore AIMD
R&D Center will immediately focus on the design and development of active
implantable medical devices to serve the Cardiovascular and Neuromodulation
markets. Both are multibillion dollar markets with considerable long-term
growth potential.
To serve the Cardiovascular
market, the company has identified needs in Interventional Procedures, Atrial
Fibrillation ablation, MRI Conditional Systems, as well as targeting health
conditions related to Cardiovascular Disease with therapies for Obesity and
Obstructive Sleep Apnea. To serve the Neuromodulation market, the company is
currently developing a Spinal Cord Stimulator called Algostim, which will treat
chronic pain in the trunk and limbs.
“The devices that the Greatbatch
Singapore AIMD R&D Center will design and develop are to be tailored to the
unique requirements that exist in emerging markets without sacrificing
physician and patient benefits,” said Daniel Kaiser, PhD., Chief Technology
Officer of Greatbatch.
“In order to develop such complex
systems we’ll focus on world class talent with the capabilities to bring these
solutions through the development and regulatory stages to serve Asia Pacific
and broader worldwide healthcare markets.”
The new center will be headed by
Kulbir Sandhu, who was formerly Senior Director of R&D at St. Jude Medical
Center in the United States. Sandhu has over 15 years of medical device
experience in the areas of new product development, program management, and
manufacturing transfer.
Greatbatch’s latest venture in
Singapore is a significant development for the country’s biomedical sector – it
is the first R&D center for active implantable medical devices in Singapore
and in Asia.
——
Source: Greatbatch,
Inc.
No comments:
Post a Comment